RELMADA THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
RELMADA THERAPEUTICS, INC. (RLMD) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 125 shares for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-12.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-05-12
- RELMADA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-03-31 was 125.00 shares.
- RELMADA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2024-09-30 was 0.00 shares.
- RELMADA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2023-12-31 was 215.31K shares.
- RELMADA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2023-03-31 was 93.75K shares.
- RELMADA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 406.41K shares, a 78.25% decline from fiscal 2022.
- RELMADA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2022 was 1.87M shares, a 308.47% increase from fiscal 2021.
- RELMADA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2021 was 457.50K shares, a 0.34% increase from fiscal 2020.
- RELMADA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2020 was 455.94K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2026-03-31 | 125.00 shares 10-Q · filed 2026-05-12 | |||
| 2024-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | 18.41K shares 10-Q · filed 2024-11-07 | ||
| 2024-06-30 | 18.41K shares 10-Q · filed 2024-08-07 | |||
| 2023-12-31 | 215.31K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | 406.41K shares 10-K · filed 2024-03-19 | ||
| 2023-09-30 | 191.10K shares 10-Q · filed 2023-11-08 | |||
| 2023-03-31 | 93.75K shares 10-Q · filed 2023-05-11 | |||
| 2022-12-31 | 1.87M shares 10-K · filed 2024-03-19 | |||
| 2021-12-31 | 457.50K shares 10-K · filed 2023-03-23 | |||
| 2020-12-31 | 455.94K shares 10-K · filed 2022-03-25 | |||
| 2015-06-30 | -206.50K shares 10-K · filed 2015-09-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |